

Curriculum Vitae

Michael Wanzel PD Dr. rer. physiol.
d.o.b. December 23th, 1971, in Marburg, Germany

University Education

2017 Habilitation Molecular Oncology, Philipps-University Marburg
2010- Senior Postdoc, Institute Molecular Oncology, Philipps-University Marburg
2004-2010 Postdoc, Institute of Molecular Biology and Tumor Research, Philipps-University Marburg
2004 Doctoral thesis, Philipps-University Marburg
1999-2004 PhD student (rer.physiol.), Institute of Molecular Biology and Tumor Research, Philipps-University Marburg
1999 Diploma thesis Humanbiology, Philipps-University Marburg
1994-1999 Studies of Humanbiology, Philipps-University Marburg

Scientific Career

2020- Member of the LOEWE Schwerpunkt iCANx
"Cancer-Lung (Disease) Crosstalk: Tumor and Organ Microenvironment"
2020- Member of "German Center for Lung Research (DZL)"
2011-2016 Member of the DFG KFO210 "Genetics of drug resistance in cancer"
2008-2013 Member of the DFG TRR17 "Ras-dependent pathways in human cancer"

Awards and Honors

2016 Poster Award, DGDR, Essen
2016 Poster Award, EACR, Amsterdam
2013 Poster Award, DZL, Bad Nauheim

Top-10 selected Publications

- Gremke N, Polo P, Dort A, Schneikert J, Elmshäuser S, Brehm C, Klingmüller U, Schmitt A, Reinhardt HC, Timofeev O, **Wanzel* M**, Stiewe* T.: mTOR-mediated cancer drug resistance suppresses autophagy and generates a druggable metabolic vulnerability. *Nat Commun.* 2020, Sep 17; 11(1):4684. doi: 10.1038/s41467-020-18504-7. (*joint last authors)
- Timofeev O, Klimovich B, Schneikert J, **Wanzel M**, Pavlakis E, Noll J, Mutlu S, Elmshäuser S, Nist A, Mernberger M, Lamp B, Wenig U, Brobeil A, Gattenlöhner S, Köhler K, Stiewe T.: Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses. *EMBO J.* 2019, Oct 15; 38(20):e102096.
- Bretz AC, Gittler MP, Charles JP, Gremke N, Eckhardt I, Mernberger M, Mandic R, Thomale J, Nist A, **Wanzel M**, Stiewe T.: Δ Np63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma. *Nucleic Acids Res*, 2016 Apr 20;44(7):3208-18.
- Wanzel M**, Vischedyk JB, Gittler MP, Gremke N, Seiz JR, Hefter M, Noack M, Savai R, Mernberger M, Charles JP, Schneikert J, Bretz AC, Nist A, Stiewe T.: CRISPR-Cas9-based target validation for p53-reactivating model compounds. *Nat Chem Biol* 2016, 12(1): 22-28.
- Charles JP, Fuchs J, Hefter M, Vischedyk JB, Kleint M, Vogiatzi F, Schäfer JA, Nist A, Timofeev O, **Wanzel M**, Stiewe T.: Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. *Nat Commun* 2014, 5:3981. doi: 10.1038/ncomms4981.
- Herkert B, Dwertmann A, Herold S, Abed M, Naud JF, Finkernagel F, Harms GS, Orian A, **Wanzel* M**, Eilers* M.: The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis. *J Cell Biol* 2010, 188 (6): 905-918. (*joint corresponding authors)
- Wanzel M**, Russ AC, Kleine-Kohlbrecher D, Colombo E, Pelicci PG, Eilers M.: A ribosomal protein L23-nucleophosmin circuit coordinates Miz1 function with cell growth. *Nat Cell Biol* 2008, 10(9): 1051-1061.
- Popov N, **Wanzel M**, Madiredjo M, Zhang D, Beijersbergen R, Bernardis R, Moll R, Elledge SJ, Eilers M.: The ubiquitin-specific protease USP28 is required for MYC stability. *Nat Cell Biol* 2007, 9(7): 765-774.
- Wanzel* M**, Kleine-Kohlbrecher* D, Herold* S, Hock A, Berns K, Park J, Hemmings B, and Eilers M.: Akt and 14-3-3 β regulate Miz1 to control cell-cycle arrest after DNA damage. *Nat Cell Biol* 2005, 7(1): 30-41. (*joint first authors)
- Herold* S, **Wanzel* M**, Beuger* V, Frohme C, Beul D, Hillukkala T, Syvaioja J, Saluz HP, Haenel F, and Eilers M.: Negative regulation of the mammalian UV response by Myc through association with Miz-1. *Mol Cell* 2002, 10(3): 509-521. (*joint first authors)